9 extractive question-and-answer pairs built from 1725952332 psychiatry depression, published by icmr.gov.in. The source is a 1-page publication. Source-evidenced topics include standard treatment workflow (stw), icd10-f45, core symptoms, additional symptoms, suicide risk assessment, amitriptyline, imipramine, mirtazapine. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. Question types in the export: 6 list, 2 factual, 1 summary. 7 of the 9 pairs (77.8%) ask explanatory questions; the remaining 2 are factual or table-based questions. 100.00% of rows pass the corpus quality gate.
This dataset contains nine question-and-answer pairs derived from a single-page publication on psychiatry and depression by icmr.gov.in. The questions address topics such as treatment timelines, additional therapies, symptoms, suicide risk assessment, and medication risks. Each answer is a verbatim excerpt from the source document, ensuring traceability. The dataset includes explanatory, factual, and list-based questions, with a focus on providing detailed insights into depression management practices.
Browse more economy datasets, including other records from the same source when available.
Explore Economy datasets1725952331_psychiatry_all - Question and Answer Dataset
Economy · 176 rows
ICMR Standard Treatment Workflow (STW) SUPRACONDYLAR FRACTURE OF HUMERUS IN CHILDREN - Question and Answer Dataset
Economy · 22 rows
1726569102_ophthalmology_all - Question and Answer Dataset
Health · 77 rows
1725952349_ent - Question and Answer Dataset
Health · 178 rows
Annual Report 2015-16 by agriwelfare.gov.in - Question and Answer Dataset
Economy · 1K+ rows
Higher Education in India - Question and Answer Dataset
Economy · 1.5K+ rows
Gender Policy of NABARD - Question and Answer Dataset
Economy · 14 rows
ICAR Annual Report 2025-26 - Question and Answer Dataset
Economy · 1.1K+ rows
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/www-icmr-gov-in-d5c35cfc6166e15f8f03fcecad228c70/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("www-icmr-gov-in-d5c35cfc6166e15f8f03fcecad228c70")
df.head()First 9 of 9 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_document | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| What is the expected timeline for improvement when using first-line medications for depression? | Improvement starts in in 2nd week and expect adequate response by 6 weeks | • Difficulty in making diagnosis • No improvement after 4 to 6 weeks of treatment with first line medications • Depression in special population: Elderly / Pregnancy / Lactation / Children / Adolescents • Comorbid medical illness / Substance use • Suicidal risk assessment • Selective Serotonin Reuptake Inhibiters (SSRI) are usually first choice (watch for GI bleed and drug interaction) • Improvement starts in in 2nd week and expect adequate response by 6 weeks • Duration of treatment typically lasts 6-9 months and Gradual tapering of medication advised for first episode • Restart SSRI , In case of resurgence and recurrence of depressive symptoms • Observe for switch / activation with Antidepressants • Watch for risk of overdose with TCA (Amitriptyline / Imipramine) and Mirtazapine • Confirm Diagnosis and Suicide risk assessment • Assess for other Medical Comorbidities • Investigations – Haemoglobin,Thyroid Function Test, Electrocardiogram • Non Responder - Switch over to SNRI (Venlafaxine 75 – 150 mg, Mirtazapine | 391 | summary | 0.970 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | • Difficulty in making diagnosis • No improvement after 4 to 6 weeks of treatment with first line medications • Depression in special population: Elderly / Pregnancy / Lactation / Children / Adolescents • Comorbid medical illness / Substance use • Suicidal risk assessment • Selective Serotonin Reuptake Inhibiters (SSRI) are usually first choice (watch for GI bleed and drug interaction) • Improvement starts in in 2nd week and expect adequate response by 6 weeks • Duration of treatment typically lasts 6-9 months and Gradual tapering of medication advised for first episode • Restart SSRI , In | 1 | page=1,block=13 | 0.700 | valid |
| What are some additional therapies that can be added for depression management? | • Cognitive Behavioral Therapy / Problem Solving Therapy • Add on Yoga Therapy / Meditation | 225mg / Imipramine 75 -225mg) • Cognitive Behavioral Therapy / Problem Solving Therapy • Add on Yoga Therapy / Meditation • Gautam S et al. Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry. 2017;59(Suppl 1):S34-S50. • Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry 2018;60, Suppl S3:341-62 • Sarkar S, Grover S. A systematic review and meta-analysis of trials of antidepressants in India for treatment of depression. Indian J Psychiatry. 2014;56:29–38 • National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004. • mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings. World Health Organisation, 2016 | 30 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | 225mg / Imipramine 75 -225mg) • Cognitive Behavioral Therapy / Problem Solving Therapy • Add on Yoga Therapy / Meditation • Gautam S et al. | ||||
| What are some cognitive symptoms associated with depression? | • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) | • Reduced concentration and attention • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness • Bleak and pessimistic views of the future • Ideas or acts of self-harm or suicide • Disturbed sleep • Diminished appetite To make a diagnosis of depression, symptoms must present for at least 2 weeks. Cognition • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) Assessment of Suicide Risk • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | 327 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | Cognition • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) Assessment of Suicide Risk • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | 1 | page=1,block=7 | 0.700 | valid |
| What are some factors assessed in suicide risk evaluation? | • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | • Reduced concentration and attention • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness • Bleak and pessimistic views of the future • Ideas or acts of self-harm or suicide • Disturbed sleep • Diminished appetite To make a diagnosis of depression, symptoms must present for at least 2 weeks. Cognition • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) Assessment of Suicide Risk • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | 443 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | Cognition • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) Assessment of Suicide Risk • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | 1 | page=1,block=7 | 0.700 | valid |
| What are some risks to monitor when using Selective Serotonin Reuptake Inhibitors (SSRIs)? | GI bleed and drug interaction | • Difficulty in making diagnosis • No improvement after 4 to 6 weeks of treatment with first line medications • Depression in special population: Elderly / Pregnancy / Lactation / Children / Adolescents • Comorbid medical illness / Substance use • Suicidal risk assessment • Selective Serotonin Reuptake Inhibiters (SSRI) are usually first choice (watch for GI bleed and drug interaction) • Improvement starts in in 2nd week and expect adequate response by 6 weeks • Duration of treatment typically lasts 6-9 months and Gradual tapering of medication advised for first episode • Restart SSRI , In case of resurgence and recurrence of depressive symptoms • Observe for switch / activation with Antidepressants • Watch for risk of overdose with TCA (Amitriptyline / Imipramine) and Mirtazapine • Confirm Diagnosis and Suicide risk assessment • Assess for other Medical Comorbidities • Investigations – Haemoglobin,Thyroid Function Test, Electrocardiogram • Non Responder - Switch over to SNRI (Venlafaxine 75 – 150 mg, Mirtazapine | 358 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | • Difficulty in making diagnosis • No improvement after 4 to 6 weeks of treatment with first line medications • Depression in special population: Elderly / Pregnancy / Lactation / Children / Adolescents • Comorbid medical illness / Substance use • Suicidal risk assessment • Selective Serotonin Reuptake Inhibiters (SSRI) are usually first choice (watch for GI bleed and drug interaction) • Improvement starts in in 2nd week and expect adequate response by 6 weeks • Duration of treatment typically lasts 6-9 months and Gradual tapering of medication advised for first episode • Restart SSRI , In | ||||
| What are some symptoms of depression related to self-perception? | • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness | • Reduced concentration and attention • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness • Bleak and pessimistic views of the future • Ideas or acts of self-harm or suicide • Disturbed sleep • Diminished appetite To make a diagnosis of depression, symptoms must present for at least 2 weeks. Cognition • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) Assessment of Suicide Risk • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | 38 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | • Reduced concentration and attention • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness • Bleak and pessimistic views of the future • Ideas or acts of self-harm or suicide • Disturbed sleep • Diminished appetite To make a diagnosis of depression, symptoms must present for at least 2 weeks. | 1 | page=1,block=7 | 0.700 | valid |
| What are some physical symptoms of depression? | • Disturbed sleep • Diminished appetite | • Reduced concentration and attention • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness • Bleak and pessimistic views of the future • Ideas or acts of self-harm or suicide • Disturbed sleep • Diminished appetite To make a diagnosis of depression, symptoms must present for at least 2 weeks. Cognition • Hopelessness (about future) • Helplessness (about others) • Worthlessness (about self) Assessment of Suicide Risk • Suicidal thoughts • Suicidal idea • Suicidal intent • Immediate risk for attempt | 198 | list | 0.780 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | • Reduced concentration and attention • Reduced self-esteem and self-confidence • Ideas of guilt and unworthiness • Bleak and pessimistic views of the future • Ideas or acts of self-harm or suicide • Disturbed sleep • Diminished appetite To make a diagnosis of depression, symptoms must present for at least 2 weeks. | 1 | page=1,block=7 | 0.700 | valid |
| What is the title of the World Health Organisation guide mentioned for mental health management? | mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings | 225mg / Imipramine 75 -225mg) • Cognitive Behavioral Therapy / Problem Solving Therapy • Add on Yoga Therapy / Meditation • Gautam S et al. Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry. 2017;59(Suppl 1):S34-S50. • Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry 2018;60, Suppl S3:341-62 • Sarkar S, Grover S. A systematic review and meta-analysis of trials of antidepressants in India for treatment of depression. Indian J Psychiatry. 2014;56:29–38 • National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004. • mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings. World Health Organisation, 2016 | 709 | factual | 0.570 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | • mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings. | ||||
| Which guidelines are referenced for the management of depression in elderly patients? | Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry 2018;60, Suppl S3:341-62 | 225mg / Imipramine 75 -225mg) • Cognitive Behavioral Therapy / Problem Solving Therapy • Add on Yoga Therapy / Meditation • Gautam S et al. Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry. 2017;59(Suppl 1):S34-S50. • Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry 2018;60, Suppl S3:341-62 • Sarkar S, Grover S. A systematic review and meta-analysis of trials of antidepressants in India for treatment of depression. Indian J Psychiatry. 2014;56:29–38 • National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004. • mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings. World Health Organisation, 2016 | 252 | factual | 0.570 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1725952332_psychiatry_depression.pdf | • Avasthi A, Grover S. Clinical practice guidelines for management of depression in elderly. Indian J Psychiatry 2018;60, Suppl S3:341-62 • Sarkar S, Grover S. |
Read straight from the file — download or use the API URL for the full dataset.
| 1 |
| page=1,block=46 |
| 0.700 |
| valid |
| 1 |
| page=1,block=13 |
| 0.700 |
| valid |
| 1 |
| page=1,block=46 |
| 0.700 |
| valid |
| 1 |
| page=1,block=46 |
| 0.700 |
| valid |